A Phase II, Multi-Centre, Randomized, Double-Blind Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA or Fulvestrant Plus Placebo in Postmenopausal Women With Bone Only or Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer.

Trial Profile

A Phase II, Multi-Centre, Randomized, Double-Blind Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA or Fulvestrant Plus Placebo in Postmenopausal Women With Bone Only or Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs Vandetanib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer; Bone metastases
  • Focus Biomarker; Therapeutic Use
  • Acronyms ZAMBONEY
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jun 2013 Primary endpoint 'Biochemical-response-rate' has not been met.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top